Undervalued Stocks in Healthcare: Novavax and Senseonics Holdings

undervalued stocks

We are looking at two undervalued stocks in the healthcare sector today! Under $5, these show potential to make some big gains in the future. Of course, penny stocks are risky so always keep that in mind before you put your money where your mouth is!

Undervalued Stocks: Novavax Inc. (NASDAQ:NVAX)

Novavax’s share price is $1.73 at present, and it is down 5% at the time of writing. Though its stock has pulled back lately, the company soared 68% in 2018—evidence of investors’ excitement.

The company is currently awaiting the results of two significant vaccine studies. These are due out in early 2019.

If successful, then Novovax’s RSV vaccine (for the respiratory syncytial virus) could receive regulatory approval in the US and Europe by early 2020.

Also, earlier in 2018 the company announced positive results from a phase 1 study of its nanoparticle-based influenza vaccine NanoFlu. The company has now advanced NanoFlu to phase 2 testing.

Enter Your E-mail Address To Subscribe

* indicates required

The stock appears to be in a cooling off period as we wait. However, Novavax’s opportunities are big if the company achieves success with either of its influenza vaccines. 

Undervalued Stocks: Senseonics Holdings (NYSE:SENS)

Looking at Senseonics’ six-month chart, stock volatility is clear to see:

Jumping from highs of $5.00 to lows of $2.90, the company reflects the great risk of penny stocks. But keep in mind that these stocks have still managed to skyrocket more than 130% this year.

>> Cannabis Penny Stocks: Namaste Adds New Craft Cannabis Line

What makes Senseonics Holdings undervalued are the copious amounts of times that the stock has hit a low. But also, an important decision that was made in March. The FDA advisory committee unanimously recommended approval for the company’s Eversense implantable CGM or continuous glucose monitoring system.

Eversense’s potential is what makes this undervalued stock undervalued. 

Stocks in diabetes offer big potential, as diabetes still affects almost 29 million people worldwide, and that number is still increasing.

But remember, there are reasons a stock trades under $5—risk factor is a big one with this lot, but if you don’t mind a good risk, the potential is here.

Featured Image: Depositphotos/© voronin-76